Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.
By S. Fröhling, R. Schlenk, J. Breitruck, Axel Benner, S. Kreitmeier, K. Tobis, H. Döhner, K. Döhner. Blood, 2002
928 citations recorded by the source corpus.
Subfields: Hematology, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/5b52c0629d22fe32a54b2898ad8110e9fe548025
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
Citations in the corpus
- Report of an international working group to standardize response criteria for myelodysplastic syndromes. (2000, background): “q11), BCR/ABL; 11q23, MLL; t(1;19)(q23;p13),E2A/PBX1;”
- Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). (2006, neutral): “Median platelet count, 109/L (range) 68 (7-302)* 56 (3-514) 47 (5-372) 46 (4-1430)”
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia (2012, neutral): “KIT mutations were associated with reduced overall survival among patients who were positive for the t(8;21) core-binding–factor alteration (P = 0.”
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. (2005, background): “In addition, a significant proportion of patients had homozygous mutations due to mitotic recombination, as has been described in patients with homozygous FLT3 mutations with retention of two copies of the FLT3 locus (Frohling et al., 2002).”
- A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. (2004, neutral): “of patients Sex Male Female 16 13 Age (years), median (range) 73 (67-82) ECOG performance status, median (range) 1 (1-3) Days from diagnosis to trial entry, median (range) 21 (6-166) FAB type M0 M1 M2 M4 M5 M6 Not classified 2 7 7 6 1 3 3 Cytogenetic risk group Adverse Intermediate Favorable 5 23 1 ”